Is Apexigen, Inc. (APGN) a Buy, Sell, or Hold?
Apexigen, Inc.
NASDAQ:APGN
$0.3851 USD
$0.03 (8.48%)
- Volume
- 94.43K
- Average Volume
- 52.6K
- Market Capitalization
- $9.57M
- P/E Ratio
- -0.24
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.28
- Year Low
- $0.33
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.29
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
16
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
59
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$5.16M
APGN Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
APGN Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Zabrowksi Dan | director | 2023-08-23 | D-Return | 2.65 | 2023-08-25 |
| Wertheimer Samuel P | director | 2023-08-23 | D-Return | 1.75 | 2023-08-25 |
| Wertheimer Samuel P | director | 2023-08-23 | D-Return | 0 | 2023-08-25 |
| Wertheimer Samuel P | director | 2023-08-23 | D-Return | 2.65 | 2023-08-25 |
| Wertheimer Samuel P | director | 2023-08-23 | D-Return | 11.5 | 2023-08-25 |
| Smith Scott Andrew | director | 2023-08-23 | D-Return | 6.94 | 2023-08-25 |
| Smith Scott Andrew | director | 2023-08-23 | D-Return | 2.65 | 2023-08-25 |
| RINGOLD GORDON | director | 2023-08-23 | D-Return | 11.5 | 2023-08-25 |
| RINGOLD GORDON | director | 2023-08-23 | D-Return | 2.65 | 2023-08-25 |
| RINGOLD GORDON | director | 2023-08-23 | D-Return | 0 | 2023-08-25 |
| RINGOLD GORDON | director | 2023-08-23 | D-Return | 4.59 | 2023-08-25 |
| Chhabra Meenu | director | 2023-08-23 | D-Return | 2.65 | 2023-08-25 |
| Dupont Jakob | director | 2023-08-23 | D-Return | 2.65 | 2023-08-25 |
| Dupont Jakob | director | 2023-08-23 | D-Return | 4.59 | 2023-08-25 |
| CROSS HERB | director | 2023-08-23 | D-Return | 2.65 | 2023-08-25 |
| CROSS HERB | director | 2023-08-23 | D-Return | 6.94 | 2023-08-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-08-23 | F-InKind | 0.3851 | 2023-08-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-08-23 | D-Return | 4.59 | 2023-08-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-08-23 | D-Return | 1.66 | 2023-08-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-08-23 | D-Return | 1.47 | 2023-08-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-08-23 | D-Return | 3.62 | 2023-08-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-08-23 | D-Return | 2.46 | 2023-08-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-08-23 | D-Return | 0 | 2023-08-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-08-23 | D-Return | 1.27 | 2023-08-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-08-23 | D-Return | 2.25 | 2023-08-25 |
| Sarena Francis Willard | officer: President and COO | 2023-08-23 | F-InKind | 0.3851 | 2023-08-25 |
| Sarena Francis Willard | officer: President and COO | 2023-08-23 | D-Return | 0 | 2023-08-25 |
| Sarena Francis Willard | officer: President and COO | 2023-08-23 | D-Return | 4.79 | 2023-08-25 |
| Hsu Frank J. | officer: Chief Medical Officer | 2023-08-23 | D-Return | 4.79 | 2023-08-25 |
| Hsu Frank J. | officer: Chief Medical Officer | 2023-08-23 | D-Return | 0 | 2023-08-25 |
| Hsu Frank J. | officer: Chief Medical Officer | 2023-08-23 | D-Return | 2.46 | 2023-08-25 |
| Duke William E. | officer: Chief Financial Officer | 2023-08-23 | F-InKind | 0.3851 | 2023-08-25 |
| Duke William E. | officer: Chief Financial Officer | 2023-08-23 | D-Return | 2.46 | 2023-08-25 |
| Duke William E. | officer: Chief Financial Officer | 2023-08-23 | D-Return | 0 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | A-Award | 0 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | F-InKind | 0.3851 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 3.62 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 6.54 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 7.03 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 4.59 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 2.46 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 11.5 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 0 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 1.27 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 1.47 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 1.66 | 2023-08-25 |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-08-23 | D-Return | 2.25 | 2023-08-25 |
| Dupont Jakob | director | 2022-07-29 | 4.49 | 2023-08-24 | |
| Yang Xiaodong | director, officer: Chief Executive Officer | 2023-06-15 | F-InKind | 0.4911 | 2023-06-23 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-06-15 | F-InKind | 0.4911 | 2023-06-23 |
| Sarena Francis Willard | officer: President and COO | 2023-06-15 | F-InKind | 0.4911 | 2023-06-23 |
| Hsu Frank J. | officer: Chief Medical Officer | 2023-06-15 | F-InKind | 0.4911 | 2023-06-23 |
| Duke William E. | officer: Chief Financial Officer | 2023-06-15 | F-InKind | 0.4911 | 2023-06-23 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-05-23 | A-Award | 0 | 2023-05-25 |
| Wong Amy | officer: SVP, Finance and Operations | 2023-05-23 | F-InKind | 0.4 | 2023-05-25 |
| Duke William E. | officer: Chief Financial Officer | 2023-05-23 | A-Award | 0 | 2023-05-25 |
| Duke William E. | officer: Chief Financial Officer | 2023-05-23 | F-InKind | 0.4 | 2023-05-25 |
| Sarena Francis Willard | officer: President and COO | 2023-05-23 | A-Award | 0 | 2023-05-25 |
| Sarena Francis Willard | officer: President and COO | 2023-05-23 | F-InKind | 0.4 | 2023-05-25 |
| Wertheimer Samuel P | director | 2023-01-26 | J-Other | 0 | 2023-05-23 |
| Wertheimer Samuel P | director | 2023-01-26 | J-Other | 11.5 | 2023-05-23 |
| Wertheimer Samuel P | director | 2023-02-21 | J-Other | 1.75 | 2023-05-23 |
| Wong Amy | officer: SVP, Finance and Operations | 2022-12-15 | F-InKind | 1.06 | 2022-12-19 |
| Sarena Francis Willard | officer: Chief Operating Officer | 2022-12-15 | F-InKind | 1.06 | 2022-12-19 |
| Hsu Frank J. | officer: Chief Medical Officer | 2022-12-15 | F-InKind | 1.06 | 2022-12-19 |
| Duke William E. | officer: Chief Financial Officer | 2022-12-15 | F-InKind | 1.06 | 2022-12-19 |
| Yang Xiaodong | officer: Chief Executive Officer | 2022-12-15 | F-InKind | 1.06 | 2022-12-19 |
| Wong Amy | officer: SVP, Finance and Operations | 2022-10-07 | A-Award | 0 | 2022-10-11 |
| Wong Amy | officer: SVP, Finance and Operations | 2022-10-07 | A-Award | 0 | 2022-10-11 |
| Sarena Francis Willard | officer: Chief Operating Officer | 2022-10-07 | A-Award | 0 | 2022-10-11 |
| Hsu Frank J. | officer: Chief Medical Officer | 2022-10-07 | A-Award | 0 | 2022-10-11 |
| Hsu Frank J. | officer: Chief Medical Officer | 2022-10-07 | A-Award | 0 | 2022-10-11 |
| Duke William E. | officer: Chief Financial Officer | 2022-10-07 | A-Award | 0 | 2022-10-11 |
| Duke William E. | officer: Chief Financial Officer | 2022-10-07 | A-Award | 0 | 2022-10-11 |
| Yang Xiaodong | officer: Chief Executive Officer | 2022-10-07 | A-Award | 0 | 2022-10-11 |
| Yang Xiaodong | officer: Chief Executive Officer | 2022-10-07 | A-Award | 0 | 2022-10-11 |
| Zabrowksi Dan | director | 2022-09-29 | A-Award | 2.65 | 2022-10-03 |
| Wertheimer Samuel P | director | 2022-09-29 | A-Award | 2.65 | 2022-10-03 |
| Smith Scott Andrew | director | 2022-09-29 | A-Award | 2.65 | 2022-10-03 |
| RINGOLD GORDON | director | 2022-09-29 | A-Award | 2.65 | 2022-10-03 |
| Chhabra Meenu | director | 2022-09-29 | A-Award | 2.65 | 2022-10-03 |
| Dupont Jakob | director: | 2022-09-29 | A-Award | 0 | 2022-10-03 |
| CROSS HERB | director: | 2022-09-29 | A-Award | 0 | 2022-10-03 |
| Zabrowksi Dan | director: | 2022-07-29 | 0 | 2022-08-08 | |
| Wertheimer Samuel P | director: | 2022-07-29 | 0 | 2022-08-08 | |
| Smith Scott Andrew | director | 2022-07-29 | 6.94 | 2022-08-08 | |
| RINGOLD GORDON | director | 2022-07-29 | 0 | 2022-08-08 | |
| RINGOLD GORDON | director | 2022-07-29 | 4.59 | 2022-08-08 | |
| RINGOLD GORDON | director | 2022-07-29 | 11.5 | 2022-08-08 | |
| Chhabra Meenu | director: | 2022-07-29 | 0 | 2022-08-08 | |
| Dupont Jakob | director | 2022-07-29 | 4.59 | 2022-08-08 | |
| CROSS HERB | director | 2022-07-29 | 6.94 | 2022-08-08 | |
| Wong Amy | officer: SVP, Finance and Operations | 2022-07-29 | 2.25 | 2022-08-08 | |
| Wong Amy | officer: SVP, Finance and Operations | 2022-07-29 | 1.27 | 2022-08-08 | |
| Wong Amy | officer: SVP, Finance and Operations | 2022-07-29 | 1.66 | 2022-08-08 | |
| Wong Amy | officer: SVP, Finance and Operations | 2022-07-29 | 1.47 | 2022-08-08 | |
| Wong Amy | officer: SVP, Finance and Operations | 2022-07-29 | 4.59 | 2022-08-08 | |
| Wong Amy | officer: SVP, Finance and Operations | 2022-07-29 | 3.62 | 2022-08-08 | |
| Sarena Francis Willard | officer: Chief Operating Officer | 2022-07-29 | 4.79 | 2022-08-08 | |
| Hsu Frank J. | officer: Chief Medical Officer | 2022-07-29 | 4.79 | 2022-08-08 |